close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

PA Health Secretary Urges Flu Shots for High-Risk Individuals

HARRISBURG, Pa., September 29, 2005 -- Pennsylvania Secretary of Health Dr. Calvin B. Johnson today emphasized the importance of Pennsylvanians who meet the definition of being at "high-risk" for influenza to get a vaccination as the flu season approaches.

"If you are over 65 or between 6 and 23 months of age, have a serious medical condition, are pregnant, provide direct patient care or live in a long-term care facility, you are considered at high risk for getting the flu and need to get a flu shot," said Dr. Johnson. "If you’re not high-risk, we’re asking you to wait until the most vulnerable people have been vaccinated - at least until Oct. 24. Last year, many Pennsylvanians ’stepped aside’ to make sure high-risk individuals received available flu vaccine first, and we’re asking them to do the same this year."

With the current uncertainties regarding available influenza vaccine doses and distribution, the Pennsylvania Department of Health and the Centers for Disease Control and Prevention (CDC) recommend that the following priority groups get their flu vaccine first, through Oct. 24, 2005:

  • persons aged 65 years and older;
  • persons aged 2-64 years with medical conditions;
  • children aged 6-23 months;
  • pregnant women;
  • residents of long-term care facilities;
  • health-care personnel who provide direct patient care;
  • out-of-home caregivers and household contacts of children aged less than 6 months; and
  • evacuees of recent hurricanes older than 6 months living in crowded group settings.

Anyone not in a high-risk group who would like a flu shot should schedule their vaccination for after Oct. 24, with their primary care provider. Healthy persons aged 5-49 years who are not pregnant, including health-care workers who are not caring for severely immunocompromised patients in special-care units, can receive the live attenuated influenza vaccine (FluMist) at any time.

Four manufacturers expect to provide more than 80 million doses of influenza vaccine nationwide this year: Sanofi Pasteur, Inc. expects production of 60 million doses; Chiron Corporation expects production of 18-26 million doses upon final Food and Drug Administration (FDA) approval; GlaxoSmithKline (GSK), Inc., whose license application was approved by the FDA on Aug. 31, 2005, expects production of 8 million doses; and MedImmune Vaccines, Inc., the producer of live attenuated influenza vaccine (FluMist), expects production of 3 million doses.

"Pennsylvania has already seen its first flu case of the season in a member of the high-risk group - a child under the age of 2 from the Philadelphia area who has recovered - which reinforces the need for priority groups to be vaccinated early," Dr. Johnson said. "While peak flu season is December through March, it is important for individuals to take the preventive measures, such as washing your hands, covering your mouth when you cough and staying home when you are sick, to reduce the chances of catching the flu."

Dr. Johnson also urged high-risk individuals to receive the pneumococcal vaccine. Pneumonia is one of the serious illnesses that can result from getting the flu.

It is also important to consult with your medical provider as soon as the first symptoms of influenza appear since certain prescription drugs (antivirals) may lessen the duration and severity of the illness if taken early. Dr. Johnson suggested consulting a physician for further information.

For more information about influenza visit the Department of Health website at www.health.state.pa.us or call the Department of Health at 1-877-PA HEALTH.

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...